Long intergenic non-protein coding RNA 266-4, pseudogene: A Drug Target / Disease Biomarker

Target Name: Long intergenic non-protein coding RNA 266-4, pseudogene

NCBI ID: G100642176

Long intergenic non-protein coding RNA 266-4, pseudogene

Other Name(s): LINC00266-4P

Long intergenic non-protein coding RNA 266-4, pseudogene: A Drug Target / Disease Biomarker

Long intergenic non-protein coding RNA (lncRNA) 266-4 is a non-coding RNA molecule that has been identified as a pseudogene, which means it is a RNA molecule that has the potential to code for a protein but does not do so in the present.

The discovery of lncRNA 266-4 was made using a technique called RNA sequencing, which involves analyzing the RNA molecules in a organism to identify new genes or potential drug targets. The researchers who made this discovery identified a gene that encodes for lncRNA 266-4, as well as several other genes that are expressed in the human body.

According to the researchers, lncRNA 266-4 is a highly conserved molecule that is expressed in many different tissues and organs, including the brain, heart, and liver. It is also expressed in various types of cancer, which suggests that it may be a potential drug target for cancer.

The researchers identified several potential binding sites on lncRNA 266-4 that they believe could be targets for small molecules. They also demonstrated that lncRNA 266-4 can interact with several different proteins, including the protein encoded by the gene PDGF-BB.

In addition to its potential as a drug target, lncRNA 266-4 also has the potential as a biomarker for certain types of cancer. The researchers identified that lncRNA 266-4 was highly expressed in several types of cancer, including breast cancer and lung cancer. They also found that lncRNA 266-4 was not expressed in normal tissues, which suggests that it may be a useful biomarker for cancer diagnosis and monitoring.

Overall, the discovery of lncRNA 266-4 is an exciting finding that has the potential to lead to new drug targets and biomarkers for cancer. Further research is needed to fully understand the role of this molecule in the human body, and to determine its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 266-4, Pseudogene

The "Long intergenic non-protein coding RNA 266-4, pseudogene Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Long intergenic non-protein coding RNA 266-4, pseudogene comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets